Selecta Biosciences (SELB) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Selecta Biosciences (NASDAQ:SELB) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.

According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “

Other equities research analysts have also recently issued reports about the stock. BidaskClub raised shares of Selecta Biosciences from a buy rating to a strong-buy rating in a report on Thursday, March 15th. Mizuho began coverage on shares of Selecta Biosciences in a report on Monday, February 26th. They issued a buy rating and a $30.00 target price for the company. ValuEngine cut shares of Selecta Biosciences from a sell rating to a strong sell rating in a report on Friday, February 2nd. Finally, Canaccord Genuity reaffirmed a buy rating and issued a $30.00 target price on shares of Selecta Biosciences in a report on Thursday, January 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Selecta Biosciences presently has a consensus rating of Buy and an average target price of $23.33.

Shares of NASDAQ:SELB opened at $12.19 on Tuesday. Selecta Biosciences has a one year low of $7.95 and a one year high of $24.02. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.20 and a quick ratio of 7.20.

Selecta Biosciences (NASDAQ:SELB) last announced its earnings results on Wednesday, May 9th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.11). Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 111.69%. equities research analysts predict that Selecta Biosciences will post -3.29 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Alps Advisors Inc. increased its stake in shares of Selecta Biosciences by 21.0% during the first quarter. Alps Advisors Inc. now owns 29,958 shares of the company’s stock worth $305,000 after acquiring an additional 5,207 shares during the period. Two Sigma Investments LP increased its stake in shares of Selecta Biosciences by 14.9% during the fourth quarter. Two Sigma Investments LP now owns 59,869 shares of the company’s stock worth $587,000 after acquiring an additional 7,773 shares during the period. BlackRock Inc. increased its stake in shares of Selecta Biosciences by 1.6% during the first quarter. BlackRock Inc. now owns 629,978 shares of the company’s stock worth $6,420,000 after acquiring an additional 9,749 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Selecta Biosciences by 50.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 29,600 shares of the company’s stock worth $541,000 after acquiring an additional 9,900 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Selecta Biosciences by 12.1% during the fourth quarter. Geode Capital Management LLC now owns 92,803 shares of the company’s stock worth $910,000 after acquiring an additional 9,988 shares during the period. Institutional investors and hedge funds own 48.24% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply